The use of chemotherapy in the treatment of early and advanced non-small-cell lung cancer
(NSCLC) has increased during the past decade. One of the main reasons for the increased …

Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …

Pemetrexed is a novel antifolate antimetabolite that targets multiple folate-dependent
enzymatic pathways and inhibits multiple enzymes involved in purine and pyrimidine …

Purpose To compare single-agent pemetrexed (P) versus the combination of carboplatin
and pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung …

O-271 Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line
chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer × …

Introduction This study prospectively evaluated the efficacy and safety of pemetrexed and
carboplatin followed by maintenance pemetrexed in chemo-naïve patients with advanced …

Purpose We performed a randomized phase II trial comparing pemetrexed with pemetrexed
plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy …

Several drugs have been approved for the treatment of patients affected by advanced non-
small cell lung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel …

Background Cisplatin plus pemetrexed is considered the standard of care for the first-line
treatment of patients with advanced non-squamous non-small-cell lung cancer (NSCLC) …

Introduction This study compared survival without toxicity in patients with advanced,
nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed …